Catalent appoints Shannon Trilli to strengthen its corporate responsibility initiatives
Will coordinate and organize the company’s existing initiatives in sustainability and maximizing social impact, and its employee-driven community programs.
Catalent Pharma Solutions has appointed Ms. Shannon Trilli in the newly created role of Director of Corporate Responsibility.
In her post, Ms Trilli will be responsible for implementing Catalent’s global corporate responsibility strategy. She will strengthen Catalent’s efforts in this area, which will continue to be led by its Corporate Responsibility Council, composed of senior Catalent leaders from multiple functions. Ms Trilli will coordinate and organize Catalent’s existing initiatives in sustainability and maximizing social impact, and its employee-driven community programs. She will also lead Catalent’s activities in establishing additional programs, including the matching of gifts and strategic volunteer initiatives, and the expansion of the organization’s philanthropic and partnership portfolio.
Before joining Catalent, she served as the Director of Corporate Responsibility at S&P Global, a leading provider of transparent and independent ratings, benchmarks, analytics and data to capital and commodity markets worldwide.
Prior to S&P Global, Ms Trilli acted as the Director of Global Health for the United Methodist Committee on Relief (UMCOR). There, she designed, scaled and led UMCOR's Signature Health Program to provide funding and technical support to community based health organizations. She also led its $75 million "Imagine No Malaria" program in sub-Saharan Africa, with partners such as the U.N. Foundation and The Global Fund.
Ms Trilli has also served as a micro-enterprise development Peace Corps volunteer in Bolivia, and early in her career, was the manager of Global Employee Programs for the Contributions and Community Relations unit of The McGraw-Hill Companies.
"In addition to more deeply engaging our communities and demonstrating Catalent's commitment to and improving health and the environment, Shannon’s appointment and implementation of the corporate responsibility strategy will help us more meaningfully connect to employees, customers, and stakeholders,” commented Alessandro Maselli, Catalent’s Senior Vice President of Global Operations. He added, “In her new role, she will help us effectively communicate how Catalent’s capabilities and values result in positive social and business impacts, both in our local communities and across the globe."
Ms Trilli earned a bachelor's in government from the University of Texas in Austin, and a master's degree in public administration from New York University.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.